Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383890 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation
A Phase 3 study, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT00383890 is a Phase 3 study that has completed, run by Hospira, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 124 participants.
The verdict
NCT00383890, a Phase 3 study, has completed, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.
Interventions
- DRUG Placebo
- DRUG Dexmedetomidine HCL Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00383890
The ClinicalTrials.gov registry entry for NCT00383890 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00383890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00383890 about?
NCT00383890 is a clinical study titled "A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation". The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.
What is the current status of trial NCT00383890?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2006-08. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00383890?
The interventions under investigation include: Placebo (DRUG), Dexmedetomidine HCL Injection (DRUG).
Who is sponsoring clinical trial NCT00383890?
This trial is sponsored by Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.